PRAX
プラクシス・プレシジョン・メディシンズ
PRAX
プラクシス・プレシジョン・メディシンズ
Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates,
Praxis Precision Medicines: Priced For Half Of What I Think It's Worth